SCHEDULE: Intracoastal Capital Amends Imunon Stake to 4.99%

Intracoastal Capital LLC and its principals have filed an amended Schedule 13G, disclosing a 4.99% beneficial ownership stake in Imunon, Inc. as of June 30, 2025.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (the "Reporting Persons") collectively hold beneficial ownership of 1,067,196 shares of Imunon, Inc. common stock.
• This ownership represents approximately 4.99% of Imunon's common stock.
• The calculation is based on 20,319,511 shares outstanding as of May 28, 2025, plus the 1,067,196 shares issuable upon exercise of Intracoastal Warrant 1.
• Intracoastal Warrant 1 includes a blocker provision, preventing exercise if it would result in beneficial ownership exceeding 4.99%.
• An additional 1,155,028 shares from Intracoastal Warrant 1 are currently excluded from beneficial ownership calculation because they are not exercisable until stockholder approval.
• Without the blocker provision and assuming current exercisability, the Reporting Persons would beneficially own 2,222,224 shares.
• The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a 13G is primarily a disclosure, the continued significant stake by an investment firm, even with a blocker, suggests ongoing interest. The passive nature (below 5% and explicit statement of no intent to influence control) reduces any potential negative activist connotations.

Positives

• A significant investment firm, Intracoastal Capital LLC, maintains a substantial stake in Imunon, Inc., indicating continued interest and confidence in the company.
• The beneficial ownership is just below the 5% threshold, which avoids triggering more stringent reporting requirements (Schedule 13D) and suggests a passive investment strategy.

Negatives

• The blocker provision in Intracoastal Warrant 1 limits the immediate exercisability of a portion of the potential shares, requiring stockholder approval for full exercise of certain warrants.

Risks

• The exercisability of 1,155,028 shares from Intracoastal Warrant 1 is contingent on future stockholder approval, introducing a potential delay or uncertainty in the full realization of the warrant's value.

Future Outlook

The filing does not provide forward-looking statements or guidance regarding Imunon, Inc.'s operational or financial performance, focusing solely on beneficial ownership disclosure.

Industry Context

This filing is a standard disclosure of beneficial ownership by an investment firm in a publicly traded company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact that an investment entity holds a significant stake in Imunon, Inc., which operates in the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an investment firm may be viewed positively, indicating institutional interest. The blocker provision ensures the stake remains below the 5% threshold, which might alleviate concerns about potential activist intervention.
• Company Management: Awareness of a significant, albeit passive, shareholder like Intracoastal Capital LLC.

Next Steps

• Stockholder approval will be required for the full exercisability of 1,155,028 shares from Intracoastal Warrant 1.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of beneficial ownership and does not contain information that would fundamentally alter the investment thesis for Imunon, Inc. The stake is significant but passive, and the filing itself does not provide new operational or financial data to warrant a change in investment recommendation. Investors should 'hold' and await further company-specific news or broader market developments.

Keywords

Imunon Inc, IMUN, Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, Beneficial Ownership, Common Stock, Warrant, SEC Filing, Investment Firm